|
Orthologous residues
|
|
CDK9 (human): T186‑p, CDK9 iso2 (human): T303‑p, CDK9 (mouse): T186‑p, CDK9 (rat): T186‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, western blotting
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
DRB
|
|
|
|
decrease
|
|
|
actinomycin D
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
transcription, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
EDG-1 (human)
|
|
Induces
|
inhibition
|
transcription, altered
|
co-immunoprecipitation, in vitro
|
|
RNA
|
|
Induces
|
inhibition
|
transcription, altered
|
co-immunoprecipitation, in vitro
|
|
|
Comments:
T186 phosporylation is important for CDK9-7SK interaction in vitro and in vivo.
|
